Epitope-based vaccine against influenza

Expert Review of Vaccines

Volumn 6, Issue 6, 2007, Pages 939-948

  Ben Yedidia, Tamar ^b   Arnon, Ruth ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b BIONDVAX PHARMACEUTICALS LTD   (Israel)

Author keywords

Broad spectrum; Cancer; Epitope; Flagella; Influenza; Peptide; Recombinant; Vaccine

Indexed keywords

FLAGELLIN; FLUBLOK; INFLUENZA VACCINE; NOVASOME; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; VIRUS VECTOR;

CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; HUMAN; IMMUNE RESPONSE; INFLUENZA; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; T LYMPHOCYTE ACTIVATION; UNSPECIFIED SIDE EFFECT; VIRUS STRAIN;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, VIRAL; DISEASE MODELS, ANIMAL; DRUG DESIGN; EPITOPE MAPPING; EPITOPES; FLAGELLIN; HUMANS; INFLUENZA VACCINES; ORTHOMYXOVIRIDAE; RECOMBINANT PROTEINS;

EID: 37149052106     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.6.6.939     Document Type: Review

References (71)

1. Maassab H, Herlocher M, Bryant M. Live influenza virus vaccine. In: Vaccines (3rd Edition). Plotkin SA, Orenstein WA (Eds). WB Saunders, PA, USA, 909-927 (1999).
2. Manzoli L, Schioppa F, Boccia A, Villari P. The efficacy of influenza vaccine for healthy children: a meta-analysis evaluating potential sources of variation in efficacy estimates including study quality. Pediatr. Infect. Dis. J. 26(2), 97-106 (2007).
3. Jefferson T, Rivetti D, Di Pietrantonj C, Rivetti A, Demicheli V. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst. Rev. CD001269 (2007). • Comprehensive review summarizing all clinical trials performed with influenza vaccines during the years 1966-2006.
4. Hoelscher M, Garg S, Bangari D et al. Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet 367(9509), 475-481 (2006).
5. Gao W, Soloff A, Lu X et al. Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization. J. Virol. 80(4), 1959-1964 (2006).
6. Pushko P, Tumpey T, Van Hoeven N et al. Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza. Vaccine 25(21), 4283-4290 (2007).
7. Treanor J, Schiff G, Couch R et al. Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenzavirus hemagglutinin vaccine in elderly adults. J. Infect. Dis. 9, 1223-1228 (2006).
8. Schultz-Cherry S, Dybing J, Davis N et al. Influenza virus (A/HK/156/97) hemagglutinin expressed by an alphavirus replicon system protect chickens against a lethal infection with Hong Kong-origin H5N1 viruses. Virology 278, 55-59 (2000).
9. Nicolson C, Major D, Wood J, Robertson J. Generation of influenza vaccine viruses on Vero cells by reverse genetics: an H5N1 candidate vaccine strain produced under a quality system. Vaccine 23(22), 2943-2952 (2005). • Demonstrates a novel approach to vaccine production that includes both virus manipulation and advanced growth of the virus in Vero cells that leads to a candidate vaccine against H5N1 virus.
10. Munoz F. Technology evaluation: FluINsure, ID Biomedical. Curr. Opin. Mol. Ther. 6(2), 212-220 (2004).
11. Reichelderfer P, Kendal A. Influenza control: new vaccines and antivirals with broad efficacy against influenza virus are needed. Drug News Perspect. 2, 99-105 (1989).
12. Ben-Yedidia T, Marcus H, Reisner Y, Arnon R. Intranasal administration of peptide vaccine protects human/mouse radiation chimera from influenza infection. Int. Immunol. 11, 1043-1051 (1999). • Explains the epitope-based approach and its ability to confer cross-strain protection in an advanced animal model.
13. Jameson J, Cruz J, Ennis F. Human cytotoxic T-lymphocyte repertoire to influenza A viruses. J. Virol. 72(11), 8682-8689 (1998).
14. De Filette M, Fiers W, Martens W et al. Improved design and intranasal delivery of an M2e-based human influenza A vaccine. Vaccine 24(44-46), 6597-6601 (2006). • Describes an epitope-based vaccine that consists of the conserved M2e region administered via the intranasal route.
15. Jegerlehner A, Schmitz N, Storni T, Bachmann M. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J. Immunol. 172, 5598-5605 (2004).
16. Delaney A. Chapter 7. Pipeline/Commercial Insight: Influenza Data Monitor. 138-183 (2007).
17. Ben-Yedidia T, Arnon R. Design of peptide and polypeptide vaccines. Curr. Opin. Biotechnol. 8(4), 442-448 (1997).
18. Kashala O, Amador R, Valero M et al. Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21. Vaccine 20(17-18), 2263-2277 (2002).
19. Nardin E, Oliveira G, Calvo-Calle J et al. Synthetic malaria peptide vaccine elicits high levels of antibodies in vaccinees of defined HLA genotypes. J. Infect. Dis. 182(5), 1486-1496 (2000). • Deals with an epitope-based vaccine and how it confronts the HLA heterogeneity in the human population.
20. Engler O, Dai W, Sette A et al. Peptide vaccines against hepatitis B virus: from animal model to human studies. Mol. Immunol. 38(6), 457-465 (2001).
21. + T cell responses induced in chronically HIV type-1-infected patients after immunizations with an HIV type 1 lipopeptide vaccine. AIDS Res. Hum. Retroviruses 22(7), 684-694 (2006).
22. Pinto L, Berzofsky J, Fowke K et al. HIV-specific immunity following immunization with HIV synthetic envelope peptides in asymptomatic HIV-infected patients. AIDS 13(15), 2003-2012 (1999).
23. Disis M, Cheever M. HER-2/neu oncogenic protein: issues in vaccine development. Crit. Rev. Immunol. 18, 37-45 (1998).
24. Ben-Yedidia T, Arnon R. Towards an epitope-based human vaccine for influenza. Hum. Vaccin. 1(3), 95-101 (2005).
25. Hans D, Young P, Fairlie D. Current status of short synthetic peptides as vaccines. Med. Chem. 2(6), 627-646 (2006).
26. Shapira M, Jolivet M, Arnon R. A synthetic vaccine against influenza with built-in adjuvanticity. Int. J. Immunopharmacol. 7, 719-723 (1985).
27. Skehel J, Wiley D. Receptor binding and membrane fusion in virus entry: the influnza hemagglutinin. Annu. Rev. Biochem. 69, 531-569 (2000).
28. Wilson I, Skehel J, Wiley D. Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution. Nature 289, 366-373 (1981).
29. Webster R, Laver W, Air G, Schild G. Molecular mechanism of variation in influenza viruses. Nature 296(5853), 115-121 (1982).
30. Levi R, Arnon R. Synthetic recombinant influenza vaccine induces efficient long-term immunity and cross-strain protection. Vaccine 14(1), 85-92 (1996).
31. Keogh E, Fikes J, Southwood S, Celis E, Chesnut R, Sette A. Identification of new epitopes from four different tumor-associated antigens: recognition of naturally processed epitopes correlates with HLA-A*0201- binding affinity. J. Immunol. 167(2), 787-796 (2001).
32. Hsu S, Chargelegue D, Obeid O, Steward M. Synergistic effect of immunization with a peptide cocktail inducing antibody, helper and cytotoxic T-cell responses on protection against respiratory syncytial virus. J. Gen. Virol. 80(Pt 6), 1401-1405 (1999).
33. Levi R, Aboud-Pirak E, Leclerc C, Lowell G, Arnon R. Intranasal immunization of mice against influenza with synthetic peptides anchored to proteosomes. Vaccine 13, 1353-1359 (1995).
34. McEwen J, Levi R, Horwitz R, Arnon R. Synthetic recombinant vaccine expressing influenza haemagglutinin epitope in Salmonella flagellin leads to partial protection in mice. Vaccine 10, 405-411 (1992).
35. Bui H, Peters B, Assarsson E, Mbawuike I, Sette A. Ab and T cell epitopes of influenza A virus, knowledge and opportunities. Proc. Natl Acad. Sci. USA 104(1), 246-251 (2007).
36. Wang M, Lamberth K, Harndahl M et al. CTL epitopes for influenza A including the H5N1 bird flu; genome-, pathogen-, and HLA-wide screening. Vaccine 25(15), 2823-2831 (2007).
37. Ernst W, Kim H, Tumpey T et al. Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines. Vaccine 24(24), 5158-5168 (2006).
38. Zou P, Liu W, Chen Y. The epitope recognized by a monoclonal antibody in influenza A virus M2 protein is immunogenic and confers immune protection. Int. Immunopharmacol. 5(4), 631-635 (2005).
39. Milich D. Synthetic T and B recognition sites: implication for vaccine development. Adv. Immunol. 45, 195-282 (1969).
40. Arnon R, Horwitz R. Synthetic peptides as vaccines. Curr. Opin. Immunol. 4, 449-453 (1992).
41. Honko A, Sriranganathan N, Lees C, Mizel S. Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with yersinia pestis. Infect. Immun. 74(2), 1113-1120 (2006).
42. Newton S, Joys T, Anderson S, Kennedy R, Hovi M, Stocker B. Expression and immunogenicity of an 18-residue epitope of HIV1 gp41 inserted in the flagellar protein of Salmonella live vaccine. Res. Microbiol. 146(3), 203-216 (1995).
43. Stocker B. Aromatic-dependent Salmonella as anti-bacterial vaccines and as presenters of heterologous antigens or of DNA encoding them. J. Biotechnol. 83(1-2), 45-50 (2000).
44. Spreng S, Dietrich G, Weidinger G. Rational design of Salmonella-based vaccination strategies. Methods 38(2), 133-143 (2006).
45. Tsujimoto H, Uchida T, Efron P et al. Flagellin enhances NK cell proliferation and activation directly and through dendritic cell-NK cell interactions. J. Leukoc. Biol. 78, 888-897 (2005). • Explains the innate immunity conferred by flagellin and enables it to serve both as a carrier and as an adjuvant.
46. Hayashi F, Smith K, Ozinsky A et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 410(6832), 1099-1103 (2001).
47. Huleatt J, Jacobs A, Tang J et al. Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity. Vaccine 25(4), 763-775 (2007). • Concludes that immunization with fusion proteins that activate Toll-like receptors induce rapid and potent antigen-specific humoral and cellular immune responses.
48. Ben-Yedidia T, Arnon R. Effect of pre-existing carrier immunity on the efficacy of synthetic influenza vaccine. Immunol. Lett. 64, 9-15 (1998).
49. Stocker B, Newton S. Immune responses to epitopes inserted in Salmonella flagellin. Int. Rev. Immunol. 11(2), 167-178 (1994).
50. Lee A, Mackay I, Rowley M, Yap C. Measurement of antibody-producing capacity to flagellin in man. IV. Studies in autoimmune disease, allergy and after azathioprine treatment. Clin. Exp. Immunol. 9, 507-518 (1971).
51. Applequist S, Rollman E, Wareing M et al. Activation of innate immunity, inflammation, and potentiation of DNA vaccination through mammalian expression of the TLR5 agonist flagellin. J. Immunol. 175(6), 3882-3891 (2005).
52. Ben-Yedidia T, Abel L, Arnon R, Globerson A. Efficacy of anti-influenza peptide vaccine in aged mice. Mech. Ageing Dev. 104, 11-23 (1998).
53. Lubin I, Segall H, Marcus H et al. Engraftment of human peripheral blood lymphocytes in normal strains of mice. Blood 83(8), 2368-2381 (1994).
54. Bocher W, Marcus H, Shakarchy R et al. Antigen-specific B and T cells in human/mouse radiation chimera following immunization in vivo. Immunology 96(4), 634-641 (1999).
55. Segall H, Lubin I, Marcus H, Canaan A, Reisner Y. Generation of primary antigen-specific human cytotoxic T lymphocytes in human/mouse radiation chimera. Blood 88, 721-730 (1996).
56. Carmon L, Bobilev-Priel I, Brenner B et al. Characterization of novel breast carcinoma-associated BA46-derived peptides in HLA-A2.1/D(b)- β2m transgenic mice. J. Clin. Invest. 110, 453-462 (2002).
57. Gallez-Hawkins G, Villacres M, Li X, Sanborn M, Lomeli N, Zaia J. Use of transgenic HLA A*0201/Kb and HHD II mice to evaluate frequency of cytomegalovirus IE1-derived peptide usage in eliciting human CD8 cytokine response. J. Virol. 77, 4457-4462 (2003).
58. +) T lymphocytes from β2 microglobulin (β2m) HLA-A2.1 monochain transgenic H-2Db β2m double knockout mice. J. Exp. Med. 185(12), 2043-2051 (1997).
59. Schreurs M, Kueter E, Scholten K, Lemmonier F, Meijer C, Hooijberg E. A single amino acid substitution improves the in vivo immunogenicity of the HPV16 oncoprotein E7(11-20) cytotoxic T lymphocyte epitope. Vaccine 23, 4005-4010 (2005).
60. + T-cell peptide epitope of vaccinia and variola viruses. J. Virol. 78, 7052-7060 (2004).
61. Effective Protection of Mice from Viral Challenge by an Influenza Synthetic Recombinant Vaccine with Cross Strain Specifity. Levi R, Arnon R (Eds). CSHL Press, NY, USA (1995).
62. Colmenares C, Lopez C. Enhanced lysis of herpes simplex virus type 1-infected mouse cell lines by NC and NK effectors. J. Immunol. 136(9), 3473-3480 (1986).
63. Alter G, Teigen N, Streeck H, Rosenberg ES. Evolution of innate and adaptive effector cell functions during acute HIV-1 infection. J. Infect. Dis. 195, 1452-1460 (2007).
64. Diehl M, Münz C, Keilholz W et al. Nonclassical HLA-G molecules are classical peptide presenters. Curr. Biol. 6(3), 305-314 (1996).
65. Takeshita F, Tanaka T, Matsuda T et al. Toll-like receptor adaptor molecules enhance DNA-raised adaptive immune responses against influenza and tumors through activation of innate immunity. J. Virol. 80(13), 6218-6224 (2006).
66. WHO 56th World Health Assembly, 17 March 2003, Influenza Report www.who.int/gb/ebwha/pdf_files/wha56/ea5623.pdf
67. InformAll Database; Egg (Hen's egg) http://foodallergens.ifr.ac.uk/food. lasso?selected_food=5001#summary
68. AlphaVax www.alphavax.com/home
69. Baxter Vaccines www.baxtervaccines.com/?node_id=1247
70. PubMed www.ncbi.nlm.nih.gov/pubmed
71. The Immune Epitope Database and Analysis Resource www.immuneepitope.org